# Crizotinib resistance conferred by BRAF V600E mutation in non–small cell lung cancer harboring an oncogenic ROS1 fusion

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/crizotinib-resistance-conferred-by-braf-v600e-mutation-in-non-small-cell-lung/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Shuang Ren,Sisi Huang,Xinqing Ye,Lu-Huai Feng,Lu Yang,Chaonan Zhou,Juan Zhao,Tingting He,Junwei Wang,Bixun Li |
| Citations | 16 |
| DOI | 10.1016/j.ctarc.2021.100377 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://www.sciencedirect.com/science/article/pii/S2468294221000757/pdf |
| OpenAlex ID | https://openalex.org/W3155363928 |
| PMID | 33945921 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Lu-Huai Feng](https://scholariq.org/researchers/lu-huai-feng/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.